442 related articles for article (PubMed ID: 8530600)
1. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
3. Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study.
Wang C; Alexander G; Berman N; Salehian B; Davidson T; McDonald V; Steiner B; Hull L; Callegari C; Swerdloff RS
J Clin Endocrinol Metab; 1996 Oct; 81(10):3578-83. PubMed ID: 8855804
[TBL] [Abstract][Full Text] [Related]
4. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study.
Wang C; Eyre DR; Clark R; Kleinberg D; Newman C; Iranmanesh A; Veldhuis J; Dudley RE; Berman N; Davidson T; Barstow TJ; Sinow R; Alexander G; Swerdloff RS
J Clin Endocrinol Metab; 1996 Oct; 81(10):3654-62. PubMed ID: 8855818
[TBL] [Abstract][Full Text] [Related]
5. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
[TBL] [Abstract][Full Text] [Related]
6. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
[TBL] [Abstract][Full Text] [Related]
7. Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men.
Stuenkel CA; Dudley RE; Yen SS
J Clin Endocrinol Metab; 1991 May; 72(5):1054-9. PubMed ID: 1902483
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
[TBL] [Abstract][Full Text] [Related]
9. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate.
Anderson RA; Wu FC
J Clin Endocrinol Metab; 1996 Mar; 81(3):896-901. PubMed ID: 8772547
[TBL] [Abstract][Full Text] [Related]
10. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
[TBL] [Abstract][Full Text] [Related]
11. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men.
Jockenhövel F; Blum WF; Vogel E; Englaro P; Müller-Wieland D; Reinwein D; Rascher W; Krone W
J Clin Endocrinol Metab; 1997 Aug; 82(8):2510-3. PubMed ID: 9253326
[TBL] [Abstract][Full Text] [Related]
12. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
Wallace EM; Gow SM; Wu FC
J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.
Dobs AS; Meikle AW; Arver S; Sanders SW; Caramelli KE; Mazer NA
J Clin Endocrinol Metab; 1999 Oct; 84(10):3469-78. PubMed ID: 10522982
[TBL] [Abstract][Full Text] [Related]
14. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
Anderson RA; Wallace AM; Wu FC
J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
[TBL] [Abstract][Full Text] [Related]
15. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system.
Dobs AS; Bachorik PS; Arver S; Meikle AW; Sanders SW; Caramelli KE; Mazer NA
J Clin Endocrinol Metab; 2001 Mar; 86(3):1026-33. PubMed ID: 11238481
[TBL] [Abstract][Full Text] [Related]
16. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men.
Bhasin S; Swerdloff RS; Steiner B; Peterson MA; Meridores T; Galmirini M; Pandian MR; Goldberg R; Berman N
J Clin Endocrinol Metab; 1992 Jan; 74(1):75-83. PubMed ID: 1727832
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
Wang C; Harnett M; Dobs AS; Swerdloff RS
J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
[TBL] [Abstract][Full Text] [Related]
18. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C
J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
[TBL] [Abstract][Full Text] [Related]
19. Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester.
Behre HM; Nieschlag E
J Clin Endocrinol Metab; 1992 Nov; 75(5):1204-10. PubMed ID: 1430080
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study.
Dobs AS; Hoover DR; Chen MC; Allen R
J Clin Endocrinol Metab; 1998 Jan; 83(1):33-9. PubMed ID: 9435413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
